GSK
GSK
740 hedge funds and large institutions have $11.7B invested in GSK in 2015 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 324 increasing their positions, 231 reducing their positions, and 41 closing their positions.
51% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 41
40% more repeat investments, than reductions
Existing positions increased: 324 | Existing positions reduced: 231
2% more funds holding
Funds holding: 728 → 740 (+12)
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
0.05% less ownership
Funds ownership: 4.18% → 4.13% (-0.05%)
43% less call options, than puts
Call options by funds: $123M | Put options by funds: $215M
45% less capital invested
Capital invested by funds: $21.1B → $11.7B (-$9.42B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$230M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$56.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$51.6M |
| 4 |
SCCM
Schafer Cullen Capital Management
New York
|
+$50.6M |
| 5 |
SM
Seminole Management
New York
|
+$48.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$201M |
| 2 |
Renaissance Technologies
New York
|
-$156M |
| 3 |
SOMRS
State of Michigan Retirement System
Lansing,
Michigan
|
-$125M |
| 4 |
Jane Street
New York
|
-$83.1M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$80.6M |
GSK Hedge Fund Activity: Q1 2015 in Review
740 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q1 2015, worth a combined $11.7B — down 45% from $21.1B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new GSK positions and 41 closed out — a net gain of 21 holders — while 324 added to existing stakes and 231 trimmed.
The largest buyer was Barclays, adding an estimated $230M. The largest seller was Waddell & Reed Financial, cutting an estimated $201M.
- 740 institutional investors held GSK (GSK) as of Q1 2015, up from 728 in Q4 2014.
- Funds reported $11.7B of GSK stock for Q1 2015, down 45% quarter-over-quarter.
- 62 funds opened new GSK positions in Q1 2015 and 41 closed out, a net change of +21 holders.
- The largest GSK buyer in Q1 2015 was Barclays, an estimated $230M added.
- The largest GSK seller in Q1 2015 was Waddell & Reed Financial, an estimated $201M sold.
Based on aggregated 13F filings for Q1 2015.